IL6
Interleukin-6
As of the edition of 20 October 2026, IL6 (interleukin-6, UniProt P05231) has 9 drugs tested at it and 15 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05231
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 17
- Disease areas
- Immune system; Cancer; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Heart and blood vessels; Urinary and reproductive; Lungs and airways
- Registered trials of its drugs
- 118
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 5 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Siltuximab | Marketed | Phase 3 | Ended 2026 |
| Olokizumab | Active | Phase 3 | none listed |
| Clazakizumab | Active | Phase 3 | none listed |
| Sirukumab | Stopped | Phase 3 | none listed |
| Ziltivekimab | Active | Phase 3 | none listed |
| Pacibekitug | Active | Phase 2 | none listed |
| Vamikibart | Stopped | Phase 3 | none listed |
| PPV-06 | Active | Phase 2 | none listed |
| Mra 003 us | Went quiet | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 8 |
| Undetermined | 4 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| GSK | Route A |
| Recordati Rare Diseases | Route B |
| Recordati | Route B |
The other 12 companies at IL6
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at IL6, ranked, with the facts behind eachRequest access. Nothing is shown until you do.